ONTOLOGY REPORT - ANNOTATIONS
| Term: | nitroprusside |
|
| Accession: | CHEBI:7596
|
browse the term
|
| Definition: | An iron coordination entity that has formula C5FeN6O. |
| Synonyms: | exact_synonym: | pentacyanidonitrosylferrate(2-); pentacyanidonitrosylferrate(III) |
| | related_synonym: | C5FeN6O; InChI=1S/5CN.Fe.NO/c5*1-2;;1-2/q;;;;;2*-1; InChIKey=ASPOIVQEUUCDQT-UHFFFAOYSA-N; Nitroferricyanide; O=N[Fe--](C#N)(C#N)(C#N)(C#N)C#N; [Fe(CN)5(NO)](2-) |
| | xref_casrn: | 15078-28-1 |
| | xref: | ChemIDplus:15078-28-1 "CAS Registry Number"; DrugBank:DB00325 "DrugBank"; KEGG COMPOUND:15078-28-1 "CAS Registry Number"; KEGG COMPOUND:C07269 "KEGG COMPOUND" |
| | xref_mesh: | MESH:D009599 |
| | xref: | MolBase:329 "MolBase" |
|
|
nitroprusside
|
| G |
ACO2 |
aconitase 2, mitochondrial |
|
multiple interactions |
ISO |
22 |
41,865,129 |
41,924,993 |
RGD:6480464 |
CTD |
| G |
ACO2 |
aconitase 2, mitochondrial |
|
decreases activity |
ISO |
22 |
41,865,129 |
41,924,993 |
RGD:6480464 |
CTD |
| G |
ADM |
adrenomedullin |
|
decreases expression |
ISO |
11 |
10,326,642 |
10,328,923 |
RGD:6480464 |
CTD |
| G |
ADRBK2 |
adrenergic, beta, receptor kinase 2 |
|
affects response to substance |
ISO |
22 |
25,960,861 |
26,125,259 |
RGD:6480464 |
CTD |
| G |
AGER |
advanced glycosylation end product-specific receptor |
|
multiple interactions |
EXP |
6 |
32,148,745 |
32,152,099 |
RGD:6480464 |
CTD |
| G |
AGT |
angiotensinogen (serpin peptidase inhibitor, clade A, member 8) |
|
decreases response to substance |
ISO |
1 |
230,838,269 |
230,850,336 |
RGD:6480464 |
CTD |
| G |
AKT1 |
v-akt murine thymoma viral oncogene homolog 1 |
|
multiple interactions |
EXP |
14 |
105,235,686 |
105,262,080 |
RGD:6480464 |
CTD |
| G |
APP |
amyloid beta (A4) precursor protein |
|
multiple interactions |
ISO |
21 |
27,252,861 |
27,543,446 |
RGD:6480464 |
CTD |
| G |
APP |
amyloid beta (A4) precursor protein |
|
decreases secretion |
ISO |
21 |
27,252,861 |
27,543,446 |
RGD:6480464 |
CTD |
| G |
BAX |
BCL2-associated X protein |
|
multiple interactions |
ISO |
19 |
49,458,117 |
49,465,055 |
RGD:6480464 |
CTD |
| G |
BAX |
BCL2-associated X protein |
|
increases expression |
ISO |
19 |
49,458,117 |
49,465,055 |
RGD:6480464 |
CTD |
| G |
BAX |
BCL2-associated X protein |
|
affects localization |
ISO |
19 |
49,458,117 |
49,465,055 |
RGD:6480464 |
CTD |
| G |
BAX |
BCL2-associated X protein |
|
multiple interactions |
EXP |
19 |
49,458,117 |
49,465,055 |
RGD:6480464 |
CTD |
| G |
BAX |
BCL2-associated X protein |
|
increases expression |
EXP |
19 |
49,458,117 |
49,465,055 |
RGD:6480464 |
CTD |
| G |
BCL2 |
B-cell CLL/lymphoma 2 |
|
decreases expression |
EXP |
18 |
60,790,579 |
60,986,613 |
RGD:6480464 |
CTD |
| G |
BCL2 |
B-cell CLL/lymphoma 2 |
|
multiple interactions |
ISO |
18 |
60,790,579 |
60,986,613 |
RGD:6480464 |
CTD |
| G |
BCL2 |
B-cell CLL/lymphoma 2 |
|
decreases expression |
ISO |
18 |
60,790,579 |
60,986,613 |
RGD:6480464 |
CTD |
| G |
BCL2L1 |
BCL2-like 1 |
|
multiple interactions |
ISO |
20 |
30,252,261 |
30,310,656 |
RGD:6480464 |
CTD |
| G |
BCL2L1 |
BCL2-like 1 |
|
decreases expression |
ISO |
20 |
30,252,261 |
30,310,656 |
RGD:6480464 |
CTD |
| G |
BDKRB2 |
bradykinin receptor B2 |
|
affects response to substance |
ISO |
14 |
96,671,135 |
96,710,666 |
RGD:6480464 |
CTD |
| G |
BID |
BH3 interacting domain death agonist |
|
decreases expression |
ISO |
22 |
18,216,906 |
18,257,431 |
RGD:6480464 |
CTD |
| G |
BID |
BH3 interacting domain death agonist |
|
multiple interactions |
ISO |
22 |
18,216,906 |
18,257,431 |
RGD:6480464 |
CTD |
| G |
BIRC5 |
baculoviral IAP repeat containing 5 |
|
multiple interactions |
EXP |
17 |
76,210,277 |
76,221,716 |
RGD:6480464 |
CTD |
| G |
BIRC5 |
baculoviral IAP repeat containing 5 |
|
decreases expression |
EXP |
17 |
76,210,277 |
76,221,716 |
RGD:6480464 |
CTD |
| G |
CALCA |
calcitonin-related polypeptide alpha |
|
increases secretion |
ISO |
11 |
14,988,215 |
14,993,832 |
RGD:6480464 |
CTD |
| G |
CALCA |
calcitonin-related polypeptide alpha |
|
multiple interactions |
ISO |
11 |
14,988,215 |
14,993,832 |
RGD:6480464 |
CTD |
| G |
CALCA |
calcitonin-related polypeptide alpha |
|
increases response to substance |
ISO |
11 |
14,988,215 |
14,993,832 |
RGD:6480464 |
CTD |
| G |
CALCA |
calcitonin-related polypeptide alpha |
|
increases secretion |
ISO |
11 |
14,988,215 |
14,993,832 |
RGD:6480464 |
CTD |
| G |
CARTPT |
CART prepropeptide |
|
multiple interactions |
ISO |
5 |
71,014,990 |
71,016,875 |
RGD:6480464 |
CTD |
| G |
CASP3 |
caspase 3, apoptosis-related cysteine peptidase |
|
increases expression |
EXP |
4 |
185,548,850 |
185,570,629 |
RGD:6480464 |
CTD |
| G |
CASP3 |
caspase 3, apoptosis-related cysteine peptidase |
|
multiple interactions |
ISO |
4 |
185,548,850 |
185,570,629 |
RGD:6480464 |
CTD |
| G |
CASP3 |
caspase 3, apoptosis-related cysteine peptidase |
|
increases activity |
ISO |
4 |
185,548,850 |
185,570,629 |
RGD:6480464 |
CTD |
| G |
CASP3 |
caspase 3, apoptosis-related cysteine peptidase |
|
multiple interactions |
EXP |
4 |
185,548,850 |
185,570,629 |
RGD:6480464 |
CTD |
| G |
CASP3 |
caspase 3, apoptosis-related cysteine peptidase |
|
multiple interactions |
EXP |
4 |
185,548,850 |
185,570,629 |
RGD:6480464 |
CTD |
| G |
CASP3 |
caspase 3, apoptosis-related cysteine peptidase |
|
increases activity |
EXP |
4 |
185,548,850 |
185,570,629 |
RGD:6480464 |
CTD |
| G |
CASP3 |
caspase 3, apoptosis-related cysteine peptidase |
|
increases activity |
ISO |
4 |
185,548,850 |
185,570,629 |
RGD:6480464 |
CTD |
| G |
CASP7 |
caspase 7, apoptosis-related cysteine peptidase |
|
increases expression |
EXP |
10 |
115,438,921 |
115,490,668 |
RGD:6480464 |
CTD |
| G |
CASP7 |
caspase 7, apoptosis-related cysteine peptidase |
|
increases activity |
ISO |
10 |
115,438,921 |
115,490,668 |
RGD:6480464 |
CTD |
| G |
CASP7 |
caspase 7, apoptosis-related cysteine peptidase |
|
multiple interactions |
ISO |
10 |
115,438,921 |
115,490,668 |
RGD:6480464 |
CTD |
| G |
CASP7 |
caspase 7, apoptosis-related cysteine peptidase |
|
increases activity |
EXP |
10 |
115,438,921 |
115,490,668 |
RGD:6480464 |
CTD |
| G |
CASP7 |
caspase 7, apoptosis-related cysteine peptidase |
|
multiple interactions |
EXP |
10 |
115,438,921 |
115,490,668 |
RGD:6480464 |
CTD |
| G |
CASP8 |
caspase 8, apoptosis-related cysteine peptidase |
|
increases activity |
ISO |
2 |
202,098,166 |
202,152,434 |
RGD:6480464 |
CTD |
| G |
CASP8 |
caspase 8, apoptosis-related cysteine peptidase |
|
multiple interactions |
ISO |
2 |
202,098,166 |
202,152,434 |
RGD:6480464 |
CTD |
| G |
CASP8 |
caspase 8, apoptosis-related cysteine peptidase |
|
multiple interactions |
EXP |
2 |
202,098,166 |
202,152,434 |
RGD:6480464 |
CTD |
| G |
CASP9 |
caspase 9, apoptosis-related cysteine peptidase |
|
decreases activity |
EXP |
1 |
15,818,769 |
15,851,285 |
RGD:6480464 |
CTD |
| G |
CASP9 |
caspase 9, apoptosis-related cysteine peptidase |
|
increases activity |
EXP |
1 |
15,818,769 |
15,851,285 |
RGD:6480464 |
CTD |
| G |
CASP9 |
caspase 9, apoptosis-related cysteine peptidase |
|
multiple interactions |
EXP |
1 |
15,818,769 |
15,851,285 |
RGD:6480464 |
CTD |
| G |
CAT |
catalase |
|
increases activity |
ISO |
11 |
34,460,472 |
34,493,607 |
RGD:6480464 |
CTD |
| G |
CAV1 |
caveolin 1, caveolae protein, 22kDa |
|
multiple interactions |
EXP |
7 |
116,164,839 |
116,201,239 |
RGD:6480464 |
CTD |
| G |
CAV1 |
caveolin 1, caveolae protein, 22kDa |
|
increases expression |
EXP |
7 |
116,164,839 |
116,201,239 |
RGD:6480464 |
CTD |
| G |
CCL2 |
chemokine (C-C motif) ligand 2 |
|
multiple interactions |
ISO |
17 |
32,582,296 |
32,584,222 |
RGD:6480464 |
CTD |
| G |
CDK1 |
cyclin-dependent kinase 1 |
|
decreases phosphorylation |
EXP |
10 |
62,538,089 |
62,554,610 |
RGD:6480464 |
CTD |
| G |
CDKN1A |
cyclin-dependent kinase inhibitor 1A (p21, Cip1) |
|
multiple interactions |
EXP |
6 |
36,644,237 |
36,655,116 |
RGD:6480464 |
CTD |
| G |
CHAT |
choline O-acetyltransferase |
|
multiple interactions |
ISO |
10 |
50,817,141 |
50,873,150 |
RGD:6480464 |
CTD |
| G |
CHAT |
choline O-acetyltransferase |
|
decreases activity |
ISO |
10 |
50,817,141 |
50,873,150 |
RGD:6480464 |
CTD |
| G |
COL1A2 |
collagen, type I, alpha 2 |
|
decreases expression |
EXP |
7 |
94,023,873 |
94,060,544 |
RGD:6480464 |
CTD |
| G |
CPS1 |
carbamoyl-phosphate synthase 1, mitochondrial |
|
affects response to substance |
EXP |
2 |
211,342,406 |
211,543,831 |
RGD:6480464 |
CTD |
| G |
CRH |
corticotropin releasing hormone |
|
multiple interactions |
ISO |
8 |
67,088,612 |
67,090,846 |
RGD:6480464 |
CTD |
| G |
CRH |
corticotropin releasing hormone |
|
multiple interactions |
ISO |
8 |
67,088,612 |
67,090,846 |
RGD:6480464 |
CTD |
| G |
CRH |
corticotropin releasing hormone |
|
multiple interactions |
ISO |
8 |
67,088,612 |
67,090,846 |
RGD:6480464 |
CTD |
| G |
CRH |
corticotropin releasing hormone |
|
increases secretion |
ISO |
8 |
67,088,612 |
67,090,846 |
RGD:6480464 |
CTD |
| G |
CRH |
corticotropin releasing hormone |
|
increases secretion |
ISO |
8 |
67,088,612 |
67,090,846 |
RGD:6480464 |
CTD |
| G |
EDN1 |
endothelin 1 |
|
multiple interactions |
ISO |
6 |
12,290,529 |
12,297,427 |
RGD:6480464 |
CTD |
| G |
EDN1 |
endothelin 1 |
|
multiple interactions |
ISO |
6 |
12,290,529 |
12,297,427 |
RGD:6480464 |
CTD |
| G |
EDN3 |
endothelin 3 |
|
multiple interactions |
ISO |
20 |
57,875,499 |
57,901,047 |
RGD:6480464 |
CTD |
| G |
EDN3 |
endothelin 3 |
|
decreases expression |
ISO |
20 |
57,875,499 |
57,901,047 |
RGD:6480464 |
CTD |
| G |
EDNRB |
endothelin receptor type B |
|
multiple interactions |
ISO |
13 13 |
78,469,616 78,513,393 |
78,549,664 78,549,674 |
RGD:6480464 |
CTD |
| G |
EPO |
erythropoietin |
|
multiple interactions |
EXP |
7 |
100,318,423 |
100,321,323 |
RGD:6480464 |
CTD |
| G |
ESR1 |
estrogen receptor 1 |
|
multiple interactions |
ISO |
6 |
152,011,631 |
152,424,409 |
RGD:6480464 |
CTD |
| G |
FGF2 |
fibroblast growth factor 2 (basic) |
|
multiple interactions |
ISO |
4 |
123,747,863 |
123,819,390 |
RGD:6480464 |
CTD |
| G |
FGF2 |
fibroblast growth factor 2 (basic) |
|
decreases response to substance |
EXP |
4 |
123,747,863 |
123,819,390 |
RGD:6480464 |
CTD |
| G |
FN1 |
fibronectin 1 |
|
multiple interactions |
EXP |
2 |
216,225,177 |
216,300,791 |
RGD:6480464 |
CTD |
| G |
FOS |
FBJ murine osteosarcoma viral oncogene homolog |
|
increases expression |
ISO |
14 |
75,745,481 |
75,748,937 |
RGD:6480464 |
CTD |
| G |
FOS |
FBJ murine osteosarcoma viral oncogene homolog |
|
affects expression |
ISO |
14 |
75,745,481 |
75,748,937 |
RGD:6480464 |
CTD |
| G |
FOS |
FBJ murine osteosarcoma viral oncogene homolog |
|
increases expression |
ISO |
14 |
75,745,481 |
75,748,937 |
RGD:6480464 |
CTD |
| G |
FOS |
FBJ murine osteosarcoma viral oncogene homolog |
|
multiple interactions |
ISO |
14 |
75,745,481 |
75,748,937 |
RGD:6480464 |
CTD |
| G |
FOS |
FBJ murine osteosarcoma viral oncogene homolog |
|
multiple interactions |
ISO |
14 |
75,745,481 |
75,748,937 |
RGD:6480464 |
CTD |
| G |
FOS |
FBJ murine osteosarcoma viral oncogene homolog |
|
increases expression |
ISO |
14 |
75,745,481 |
75,748,937 |
RGD:6480464 |
CTD |
| G |
FOS |
FBJ murine osteosarcoma viral oncogene homolog |
|
affects expression |
ISO |
14 |
75,745,481 |
75,748,937 |
RGD:6480464 |
CTD |
| G |
FOS |
FBJ murine osteosarcoma viral oncogene homolog |
|
affects expression |
ISO |
14 |
75,745,481 |
75,748,937 |
RGD:6480464 |
CTD |
| G |
FOS |
FBJ murine osteosarcoma viral oncogene homolog |
|
increases expression |
ISO |
14 |
75,745,481 |
75,748,937 |
RGD:6480464 |
CTD |
| G |
G6PD |
glucose-6-phosphate dehydrogenase |
|
multiple interactions |
EXP |
X |
153,759,606 |
153,775,787 |
RGD:6480464 |
CTD |
| G |
GUCY1A3 |
guanylate cyclase 1, soluble, alpha 3 |
|
multiple interactions |
ISO |
4 |
156,587,862 |
156,658,214 |
RGD:6480464 |
CTD |
| G |
GUCY1A3 |
guanylate cyclase 1, soluble, alpha 3 |
|
multiple interactions |
ISO |
4 |
156,587,862 |
156,658,214 |
RGD:6480464 |
CTD |
| G |
GUCY1A3 |
guanylate cyclase 1, soluble, alpha 3 |
|
multiple interactions |
ISO |
4 |
156,587,862 |
156,658,214 |
RGD:6480464 |
CTD |
| G |
GUCY1A3 |
guanylate cyclase 1, soluble, alpha 3 |
|
multiple interactions |
ISO |
4 |
156,587,862 |
156,658,214 |
RGD:6480464 |
CTD |
| G |
GUCY1B3 |
guanylate cyclase 1, soluble, beta 3 |
|
multiple interactions |
ISO |
4 |
156,680,126 |
156,728,783 |
RGD:6480464 |
CTD |
| G |
GUCY1B3 |
guanylate cyclase 1, soluble, beta 3 |
|
multiple interactions |
ISO |
4 |
156,680,126 |
156,728,783 |
RGD:6480464 |
CTD |
| G |
GUCY1B3 |
guanylate cyclase 1, soluble, beta 3 |
|
multiple interactions |
ISO |
4 |
156,680,126 |
156,728,783 |
RGD:6480464 |
CTD |
| G |
GUCY1B3 |
guanylate cyclase 1, soluble, beta 3 |
|
multiple interactions |
ISO |
4 |
156,680,126 |
156,728,783 |
RGD:6480464 |
CTD |
| G |
HIF1A |
hypoxia inducible factor 1, alpha subunit (basic helix-loop-helix transcription factor) |
|
decreases activity |
EXP |
14 |
62,162,119 |
62,214,977 |
RGD:6480464 |
CTD |
| G |
HIF1A |
hypoxia inducible factor 1, alpha subunit (basic helix-loop-helix transcription factor) |
|
decreases expression |
EXP |
14 |
62,162,119 |
62,214,977 |
RGD:6480464 |
CTD |
| G |
HIF1A |
hypoxia inducible factor 1, alpha subunit (basic helix-loop-helix transcription factor) |
|
multiple interactions |
EXP |
14 |
62,162,119 |
62,214,977 |
RGD:6480464 |
CTD |
| G |
HMOX1 |
heme oxygenase (decycling) 1 |
|
multiple interactions |
EXP |
22 |
35,777,060 |
35,790,207 |
RGD:6480464 |
CTD |
| G |
HMOX1 |
heme oxygenase (decycling) 1 |
|
increases expression |
EXP |
22 |
35,777,060 |
35,790,207 |
RGD:6480464 |
CTD |
| G |
HMOX1 |
heme oxygenase (decycling) 1 |
|
multiple interactions |
ISO |
22 |
35,777,060 |
35,790,207 |
RGD:6480464 |
CTD |
| G |
HMOX1 |
heme oxygenase (decycling) 1 |
|
multiple interactions |
ISO |
22 |
35,777,060 |
35,790,207 |
RGD:6480464 |
CTD |
| G |
HMOX1 |
heme oxygenase (decycling) 1 |
|
decreases expression |
ISO |
22 |
35,777,060 |
35,790,207 |
RGD:6480464 |
CTD |
| G |
HMOX1 |
heme oxygenase (decycling) 1 |
|
increases expression |
ISO |
22 |
35,777,060 |
35,790,207 |
RGD:6480464 |
CTD |
| G |
HMOX1 |
heme oxygenase (decycling) 1 |
|
multiple interactions |
EXP |
22 |
35,777,060 |
35,790,207 |
RGD:6480464 |
CTD |
| G |
HNRPDL |
heterogeneous nuclear ribonucleoprotein D-like |
|
multiple interactions |
EXP |
4 |
83,343,717 |
83,351,378 |
RGD:6480464 |
CTD |
| G |
HSPA1L |
heat shock 70kDa protein 1-like |
|
multiple interactions |
EXP |
6 |
31,777,396 |
31,782,835 |
RGD:6480464 |
CTD |
| G |
HSPD1 |
heat shock 60kDa protein 1 (chaperonin) |
|
multiple interactions |
EXP |
2 |
198,351,308 |
198,364,998 |
RGD:6480464 |
CTD |
| G |
IBSP |
integrin-binding sialoprotein |
|
multiple interactions |
EXP |
4 |
88,720,702 |
88,733,601 |
RGD:6480464 |
CTD |
| G |
IBSP |
integrin-binding sialoprotein |
|
increases expression |
EXP |
4 |
88,720,702 |
88,733,601 |
RGD:6480464 |
CTD |
| G |
IFNG |
interferon, gamma |
|
decreases expression |
EXP |
12 |
68,548,550 |
68,553,521 |
RGD:6480464 |
CTD |
| G |
IFNG |
interferon, gamma |
|
multiple interactions |
ISO |
12 |
68,548,550 |
68,553,521 |
RGD:6480464 |
CTD |
| G |
IFNG |
interferon, gamma |
|
multiple interactions |
EXP |
12 |
68,548,550 |
68,553,521 |
RGD:6480464 |
CTD |
| G |
IGF1 |
insulin-like growth factor 1 (somatomedin C) |
|
decreases response to substance |
EXP |
12 |
102,789,645 |
102,874,378 |
RGD:6480464 |
CTD |
| G |
IGF1 |
insulin-like growth factor 1 (somatomedin C) |
|
multiple interactions |
ISO |
12 |
102,789,645 |
102,874,378 |
RGD:6480464 |
CTD |
| G |
IL1B |
interleukin 1, beta |
|
multiple interactions |
EXP |
2 |
113,587,337 |
113,594,356 |
RGD:6480464 |
CTD |
| G |
IL4 |
interleukin 4 |
|
decreases expression |
EXP |
5 |
132,009,678 |
132,018,370 |
RGD:6480464 |
CTD |
| G |
IL4 |
interleukin 4 |
|
multiple interactions |
ISO |
5 |
132,009,678 |
132,018,370 |
RGD:6480464 |
CTD |
| G |
IL4 |
interleukin 4 |
|
increases expression |
ISO |
5 |
132,009,678 |
132,018,370 |
RGD:6480464 |
CTD |
| G |
ITGB3 |
integrin, beta 3 (platelet glycoprotein IIIa, antigen CD61) |
|
multiple interactions |
EXP |
17 |
45,331,208 |
45,390,077 |
RGD:6480464 |
CTD |
| G |
JUN |
jun proto-oncogene |
|
affects localization |
ISO |
1 |
59,246,463 |
59,249,785 |
RGD:6480464 |
CTD |
| G |
JUNB |
jun B proto-oncogene |
|
increases expression |
ISO |
19 |
12,902,310 |
12,904,125 |
RGD:6480464 |
CTD |
| G |
KCNJ2 |
potassium inwardly-rectifying channel, subfamily J, member 2 |
|
affects activity |
ISO |
17 |
68,165,676 |
68,176,185 |
RGD:6480464 |
CTD |
| G |
KNG1 |
kininogen 1 |
|
decreases activity |
ISO |
3 |
186,435,098 |
186,462,199 |
RGD:6480464 |
CTD |
| G |
MAOA |
monoamine oxidase A |
|
multiple interactions |
ISO |
X |
43,514,155 |
43,606,071 |
RGD:6480464 |
CTD |
| G |
MAOB |
monoamine oxidase B |
|
multiple interactions |
ISO |
X |
43,625,857 |
43,741,721 |
RGD:6480464 |
CTD |
| G |
MAPK1 |
mitogen-activated protein kinase 1 |
|
decreases phosphorylation |
EXP |
22 |
22,113,946 |
22,221,970 |
RGD:6480464 |
CTD |
| G |
MAPK1 |
mitogen-activated protein kinase 1 |
|
multiple interactions |
EXP |
22 |
22,113,946 |
22,221,970 |
RGD:6480464 |
CTD |
| G |
MAPK1 |
mitogen-activated protein kinase 1 |
|
multiple interactions |
ISO |
22 |
22,113,946 |
22,221,970 |
RGD:6480464 |
CTD |
| G |
MAPK1 |
mitogen-activated protein kinase 1 |
|
multiple interactions |
ISO |
22 |
22,113,946 |
22,221,970 |
RGD:6480464 |
CTD |
| G |
MAPK1 |
mitogen-activated protein kinase 1 |
|
increases phosphorylation |
ISO |
22 |
22,113,946 |
22,221,970 |
RGD:6480464 |
CTD |
| G |
MAPK1 |
mitogen-activated protein kinase 1 |
|
multiple interactions |
EXP |
22 |
22,113,946 |
22,221,970 |
RGD:6480464 |
CTD |
| G |
MAPK1 |
mitogen-activated protein kinase 1 |
|
decreases expression |
ISO |
22 |
22,113,946 |
22,221,970 |
RGD:6480464 |
CTD |
| G |
MAPK3 |
mitogen-activated protein kinase 3 |
|
decreases phosphorylation |
EXP |
16 |
30,125,426 |
30,134,630 |
RGD:6480464 |
CTD |
| G |
MAPK3 |
mitogen-activated protein kinase 3 |
|
multiple interactions |
ISO |
16 |
30,125,426 |
30,134,630 |
RGD:6480464 |
CTD |
| G |
MAPK3 |
mitogen-activated protein kinase 3 |
|
multiple interactions |
EXP |
16 |
30,125,426 |
30,134,630 |
RGD:6480464 |
CTD |
| G |
MAPK3 |
mitogen-activated protein kinase 3 |
|
multiple interactions |
ISO |
16 |
30,125,426 |
30,134,630 |
RGD:6480464 |
CTD |
| G |
MAPK3 |
mitogen-activated protein kinase 3 |
|
increases phosphorylation |
ISO |
16 |
30,125,426 |
30,134,630 |
RGD:6480464 |
CTD |
| G |
MAPK3 |
mitogen-activated protein kinase 3 |
|
multiple interactions |
EXP |
16 |
30,125,426 |
30,134,630 |
RGD:6480464 |
CTD |
| G |
MAPK3 |
mitogen-activated protein kinase 3 |
|
affects response to substance |
ISO |
16 |
30,125,426 |
30,134,630 |
RGD:6480464 |
CTD |
| G |
MAPK3 |
mitogen-activated protein kinase 3 |
|
multiple interactions |
ISO |
16 |
30,125,426 |
30,134,630 |
RGD:6480464 |
CTD |
| G |
MAPK3 |
mitogen-activated protein kinase 3 |
|
decreases expression |
ISO |
16 |
30,125,426 |
30,134,630 |
RGD:6480464 |
CTD |
| G |
MAPK8 |
mitogen-activated protein kinase 8 |
|
multiple interactions |
EXP |
10 |
49,609,687 |
49,643,183 |
RGD:6480464 |
CTD |
| G |
MAPK8 |
mitogen-activated protein kinase 8 |
|
decreases expression |
ISO |
10 |
49,609,687 |
49,643,183 |
RGD:6480464 |
CTD |
| G |
MAPK8 |
mitogen-activated protein kinase 8 |
|
multiple interactions |
ISO |
10 |
49,609,687 |
49,643,183 |
RGD:6480464 |
CTD |
| G |
MAPK8 |
mitogen-activated protein kinase 8 |
|
affects response to substance |
ISO |
10 |
49,609,687 |
49,643,183 |
RGD:6480464 |
CTD |
| G |
MAPK9 |
mitogen-activated protein kinase 9 |
|
multiple interactions |
EXP |
5 |
179,660,594 |
179,719,071 |
RGD:6480464 |
CTD |
| G |
MAPK9 |
mitogen-activated protein kinase 9 |
|
decreases expression |
ISO |
5 |
179,660,594 |
179,719,071 |
RGD:6480464 |
CTD |
| G |
MCL1 |
myeloid cell leukemia sequence 1 (BCL2-related) |
|
multiple interactions |
EXP |
1 |
150,547,027 |
150,552,214 |
RGD:6480464 |
CTD |
| G |
MT1A |
metallothionein 1A |
|
increases expression |
EXP |
16 |
56,672,578 |
56,673,999 |
RGD:6480464 |
CTD |
| G |
MT1A |
metallothionein 1A |
|
multiple interactions |
EXP |
16 |
56,672,578 |
56,673,999 |
RGD:6480464 |
CTD |
| G |
MT1E |
metallothionein 1E |
|
increases expression |
EXP |
16 |
56,659,585 |
56,661,024 |
RGD:6480464 |
CTD |
| G |
MT1E |
metallothionein 1E |
|
multiple interactions |
EXP |
16 |
56,659,585 |
56,661,024 |
RGD:6480464 |
CTD |
| G |
MT1X |
metallothionein 1X |
|
increases expression |
EXP |
16 |
56,716,382 |
56,718,108 |
RGD:6480464 |
CTD |
| G |
MT1X |
metallothionein 1X |
|
multiple interactions |
EXP |
16 |
56,716,382 |
56,718,108 |
RGD:6480464 |
CTD |
| G |
MT2A |
metallothionein 2A |
|
multiple interactions |
EXP |
16 |
56,642,478 |
56,643,409 |
RGD:6480464 |
CTD |
| G |
MT2A |
metallothionein 2A |
|
increases expression |
EXP |
16 |
56,642,478 |
56,643,409 |
RGD:6480464 |
CTD |
| G |
MT2A |
metallothionein 2A |
|
multiple interactions |
EXP |
16 |
56,642,478 |
56,643,409 |
RGD:6480464 |
CTD |
| G |
MTF1 |
metal-regulatory transcription factor 1 |
|
multiple interactions |
EXP |
1 |
38,275,239 |
38,325,292 |
RGD:6480464 |
CTD |
| G |
MTF1 |
metal-regulatory transcription factor 1 |
|
increases expression |
EXP |
1 |
38,275,239 |
38,325,292 |
RGD:6480464 |
CTD |
| G |
MYC |
v-myc myelocytomatosis viral oncogene homolog (avian) |
|
decreases expression |
EXP |
8 |
128,748,315 |
128,753,680 |
RGD:6480464 |
CTD |
| G |
NFKBIA |
nuclear factor of kappa light polypeptide gene enhancer in B-cells inhibitor, alpha |
|
multiple interactions |
ISO |
14 |
35,870,716 |
35,873,960 |
RGD:6480464 |
CTD |
| G |
NOS1 |
nitric oxide synthase 1 (neuronal) |
|
multiple interactions |
EXP |
12 |
117,645,947 |
117,799,607 |
RGD:6480464 |
CTD |
| G |
NOS2 |
nitric oxide synthase 2, inducible |
|
multiple interactions |
ISO |
17 |
26,083,792 |
26,127,555 |
RGD:6480464 |
CTD |
| G |
NOS2 |
nitric oxide synthase 2, inducible |
|
decreases activity |
EXP |
17 |
26,083,792 |
26,127,555 |
RGD:6480464 |
CTD |
| G |
NOS2 |
nitric oxide synthase 2, inducible |
|
multiple interactions |
EXP |
17 |
26,083,792 |
26,127,555 |
RGD:6480464 |
CTD |
| G |
NOS3 |
nitric oxide synthase 3 (endothelial cell) |
|
multiple interactions |
EXP |
7 |
150,688,144 |
150,711,687 |
RGD:6480464 |
CTD |
| G |
NPPB |
natriuretic peptide B |
|
decreases expression |
EXP |
1 |
11,917,521 |
11,918,992 |
RGD:6480464 |
CTD |
| G |
PLG |
plasminogen |
|
decreases response to substance |
ISO |
6 |
161,123,225 |
161,175,086 |
RGD:6480464 |
CTD |
| G |
POMC |
proopiomelanocortin |
|
multiple interactions |
ISO |
2 |
25,383,722 |
25,391,559 |
RGD:6480464 |
CTD |
| G |
POMC |
proopiomelanocortin |
|
increases secretion |
ISO |
2 |
25,383,722 |
25,391,559 |
RGD:6480464 |
CTD |
| G |
POMC |
proopiomelanocortin |
|
multiple interactions |
ISO |
2 |
25,383,722 |
25,391,559 |
RGD:6480464 |
CTD |
| G |
PPARGC1A |
peroxisome proliferator-activated receptor gamma, coactivator 1 alpha |
|
multiple interactions |
EXP |
4 |
23,793,644 |
23,891,700 |
RGD:6480464 |
CTD |
| G |
PRKG1 |
protein kinase, cGMP-dependent, type I |
|
multiple interactions |
EXP |
10 |
52,750,911 |
54,058,110 |
RGD:6480464 |
CTD |
| G |
PRNP |
prion protein |
|
multiple interactions |
EXP |
20 |
4,666,797 |
4,682,234 |
RGD:6480464 |
CTD |
| G |
PTGS2 |
prostaglandin-endoperoxide synthase 2 (prostaglandin G/H synthase and cyclooxygenase) |
|
multiple interactions |
ISO |
1 |
186,640,944 |
186,649,559 |
RGD:6480464 |
CTD |
| G |
RAMP2 |
receptor (G protein-coupled) activity modifying protein 2 |
|
increases expression |
ISO |
17 |
40,913,212 |
40,915,059 |
RGD:6480464 |
CTD |
| G |
RASD1 |
RAS, dexamethasone-induced 1 |
|
multiple interactions |
ISO |
17 |
17,397,751 |
17,399,709 |
RGD:6480464 |
CTD |
| G |
REN |
renin |
|
multiple interactions |
EXP |
1 |
204,123,944 |
204,135,465 |
RGD:6480464 |
CTD |
| G |
REN |
renin |
|
multiple interactions |
EXP |
1 |
204,123,944 |
204,135,465 |
RGD:6480464 |
CTD |
| G |
REN |
renin |
|
multiple interactions |
EXP |
1 |
204,123,944 |
204,135,465 |
RGD:6480464 |
CTD |
| G |
REN |
renin |
|
multiple interactions |
EXP |
1 |
204,123,944 |
204,135,465 |
RGD:6480464 |
CTD |
| G |
REN |
renin |
|
multiple interactions |
EXP |
1 |
204,123,944 |
204,135,465 |
RGD:6480464 |
CTD |
| G |
REN |
renin |
|
multiple interactions |
EXP |
1 |
204,123,944 |
204,135,465 |
RGD:6480464 |
CTD |
| G |
REN |
renin |
|
increases activity |
EXP |
1 |
204,123,944 |
204,135,465 |
RGD:6480464 |
CTD |
| G |
REN |
renin |
|
multiple interactions |
ISO |
1 |
204,123,944 |
204,135,465 |
RGD:6480464 |
CTD |
| G |
REN |
renin |
|
increases activity |
EXP |
1 |
204,123,944 |
204,135,465 |
RGD:6480464 |
CTD |
| G |
REN |
renin |
|
multiple interactions |
EXP |
1 |
204,123,944 |
204,135,465 |
RGD:6480464 |
CTD |
| G |
REN |
renin |
|
increases activity |
EXP |
1 |
204,123,944 |
204,135,465 |
RGD:6480464 |
CTD |
| G |
REN |
renin |
|
increases activity |
EXP |
1 |
204,123,944 |
204,135,465 |
RGD:6480464 |
CTD |
| G |
REN |
renin |
|
increases activity |
EXP |
1 |
204,123,944 |
204,135,465 |
RGD:6480464 |
CTD |
| G |
REN |
renin |
|
increases activity |
EXP |
1 |
204,123,944 |
204,135,465 |
RGD:6480464 |
CTD |
| G |
REN |
renin |
|
increases activity |
EXP |
1 |
204,123,944 |
204,135,465 |
RGD:6480464 |
CTD |
| G |
RETN |
resistin |
|
decreases expression |
ISO |
19 |
7,733,972 |
7,735,340 |
RGD:6480464 |
CTD |
| G |
SIRT1 |
sirtuin 1 |
|
multiple interactions |
EXP |
10 |
69,644,427 |
69,678,147 |
RGD:6480464 |
CTD |
| G |
SLC11A2 |
solute carrier family 11 (proton-coupled divalent metal ion transporters), member 2 |
|
multiple interactions |
EXP |
12 |
51,373,566 |
51,422,058 |
RGD:6480464 |
CTD |
| G |
SLC30A1 |
solute carrier family 30 (zinc transporter), member 1 |
|
multiple interactions |
EXP |
1 |
211,748,381 |
211,752,099 |
RGD:6480464 |
CTD |
| G |
SLC30A1 |
solute carrier family 30 (zinc transporter), member 1 |
|
increases expression |
EXP |
1 |
211,748,381 |
211,752,099 |
RGD:6480464 |
CTD |
| G |
SOD1 |
superoxide dismutase 1, soluble |
|
multiple interactions |
EXP |
21 |
33,031,935 |
33,041,244 |
RGD:6480464 |
CTD |
| G |
SOD2 |
superoxide dismutase 2, mitochondrial |
|
multiple interactions |
EXP |
6 |
160,100,148 |
160,114,353 |
RGD:6480464 |
CTD |
| G |
SPP1 |
secreted phosphoprotein 1 |
|
multiple interactions |
EXP |
4 |
88,896,802 |
88,904,563 |
RGD:6480464 |
CTD |
| G |
SPP1 |
secreted phosphoprotein 1 |
|
increases expression |
EXP |
4 |
88,896,802 |
88,904,563 |
RGD:6480464 |
CTD |
| G |
SPTAN1 |
spectrin, alpha, non-erythrocytic 1 |
|
increases cleavage |
ISO |
9 |
131,314,837 |
131,395,944 |
RGD:6480464 |
CTD |
| G |
SPTAN1 |
spectrin, alpha, non-erythrocytic 1 |
|
multiple interactions |
ISO |
9 |
131,314,837 |
131,395,944 |
RGD:6480464 |
CTD |
| G |
TACR1 |
tachykinin receptor 1 |
|
increases response to substance |
ISO |
2 |
75,273,590 |
75,426,645 |
RGD:6480464 |
CTD |
| G |
TFRC |
transferrin receptor (p90, CD71) |
|
multiple interactions |
EXP |
3 |
195,776,155 |
195,809,032 |
RGD:6480464 |
CTD |
| G |
TH |
tyrosine hydroxylase |
|
multiple interactions |
ISO |
11 |
2,185,159 |
2,193,035 |
RGD:6480464 |
CTD |
| G |
TH |
tyrosine hydroxylase |
|
multiple interactions |
ISO |
11 |
2,185,159 |
2,193,035 |
RGD:6480464 |
CTD |
| G |
TH |
tyrosine hydroxylase |
|
increases expression |
ISO |
11 |
2,185,159 |
2,193,035 |
RGD:6480464 |
CTD |
| G |
TLR2 |
toll-like receptor 2 |
|
multiple interactions |
ISO |
4 |
154,605,441 |
154,627,243 |
RGD:6480464 |
CTD |
| G |
TNF |
tumor necrosis factor |
|
decreases response to substance |
ISO |
6 |
31,543,344 |
31,546,113 |
RGD:6480464 |
CTD |
| G |
TNF |
tumor necrosis factor |
|
multiple interactions |
EXP |
6 |
31,543,344 |
31,546,113 |
RGD:6480464 |
CTD |
| G |
TP53 |
tumor protein p53 |
|
multiple interactions |
ISO |
17 |
7,571,720 |
7,590,868 |
RGD:6480464 |
CTD |
| G |
TP53 |
tumor protein p53 |
|
increases expression |
EXP |
17 |
7,571,720 |
7,590,868 |
RGD:6480464 |
CTD |
| G |
TP53 |
tumor protein p53 |
|
increases phosphorylation |
ISO |
17 |
7,571,720 |
7,590,868 |
RGD:6480464 |
CTD |
| G |
TRPV1 |
transient receptor potential cation channel, subfamily V, member 1 |
|
multiple interactions |
EXP |
17 |
3,468,740 |
3,512,705 |
RGD:6480464 |
CTD |
| G |
VEGFA |
vascular endothelial growth factor A |
|
multiple interactions |
EXP |
6 |
43,737,946 |
43,754,224 |
RGD:6480464 |
CTD |
| G |
XDH |
xanthine dehydrogenase |
|
multiple interactions |
ISO |
2 |
31,557,188 |
31,637,611 |
RGD:6480464 |
CTD |
Term paths to the root
|